Literature DB >> 9112071

Relaxin: a pleiotropic hormone.

D Bani1.   

Abstract

1. Relaxin is a peptide hormone of about 6000 Da belonging to the insulin family. Like insulin, relaxin is composed by two disulfide-linked chains, termed the A and B chains, the B chain bearing the receptor interaction site. 2. Relaxin is produced primarily by the corpus luteum, in both pregnant and nonpregnant females. It attains the highest plasma levels during pregnancy. In this condition, relaxin is also produced by the decidua and placenta. In males, relaxin is synthesized in the prostate and released in the seminal fluid. An additional source of relaxin has recently been identified in the heart atria. 3. Relaxin has a broad range of biologic activities, some of which have been known for a long time. These latter ones include: (a) the induction of collagen remodeling and consequent softening of the tissues of the birth canal in view of delivery; (b) the inhibition of uterine contractile activity; (c) the stimulation of growth and differentiation of the mammary gland. 4. In more recent years, novel sites of relaxin action have been recognized. In particular, it has been shown that relaxin: (a) regulates growth and differentiation of breast cancer cells in culture; (b) promotes dilation of blood vessels in several organs and tissues, including the uterus, the mammary gland, the lung and the heart; (c) has a chronotropic action on the heart; (d) inhibits the release of histamine by mast cells, thus being able to counteract experimental allergic asthma; (d) depresses aggregation of platelets and their release by megakaryocytes; (e) influences the secretion of hormones by the pituitary gland; and (f) contributes to the regulation of fluid balance. 5. Concerning the mechanisms of action of relaxin, stimulation of nitric oxide generation, with consequent rise in intracellular cyclic GMP levels, and stimulation of cyclic AMP production have been demonstrated to occur in the target cells and organs. 6. It may be expected that the next decade will provide answers about the utility of relaxin, in terms of insight into the actual physiologic functions of relaxin in the animal kingdom and especially in man, in view of possible therapeutic use of relaxin or relaxin-derived drugs in human disease, especially considering that human recombinant relaxin is now available for clinical experimentation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112071     DOI: 10.1016/s0306-3623(96)00171-1

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  39 in total

1.  Impaired nipple development and parturition in LGR7 knockout mice.

Authors:  Magda A M Krajnc-Franken; Ad J M van Disseldorp; Jasper E Koenders; Sietse Mosselman; Marcel van Duin; Jan A Gossen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

Authors:  E Masini; G Zagli; J F Ndisang; M Solazzo; P F Mannaioni; D Bani
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

3.  Gene duplication and positive selection explains unusual physiological roles of the relaxin gene in the European rabbit.

Authors:  José Ignacio Arroyo; Federico G Hoffmann; Juan C Opazo
Journal:  J Mol Evol       Date:  2012-02-22       Impact factor: 2.395

Review 4.  The effects of the menstrual cycle on anterior knee laxity: a systematic review.

Authors:  Bohdanna T Zazulak; Mark Paterno; Gregory D Myer; William A Romani; Timothy E Hewett
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

Review 5.  Immune response to stem cells and strategies to induce tolerance.

Authors:  Puspa Batten; Nadia A Rosenthal; Magdi H Yacoub
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

6.  Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart.

Authors:  D Bani; E Masini; M G Bello; M Bigazzi; T B Sacchi
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 7.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 8.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

9.  Studies of the molecular mechanisms of action of relaxin on the adenylyl cyclase signaling system using synthetic peptides derived from the LGR7 relaxin receptor.

Authors:  A O Shpakov; I A Gur'yanov; L A Kuznetsova; S A Plesneva; E A Shpakova; G P Vlasov; M N Pertseva
Journal:  Neurosci Behav Physiol       Date:  2007-09

10.  N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.

Authors:  C Fisher; C Berry; L Blue; J J Morton; J McMurray
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.